Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 6:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,324 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Withdraw treatment Clear all
Active, not recruiting Phase 3 Interventional

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

NCT05973773
View directory record Official record
Conditions
Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Interventions
TAS6417
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Henderson, Nevada • Las Vegas, Nevada • Canton, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs

NCT02350764
View directory record Official record
Conditions
Advanced Stage Non-small Cell Lung Cancer
Interventions
nivolumab, pilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 2 Interventional

Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV

NCT06538285
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Ketamine, Psychotherapy
Drug · Behavioral
Lead sponsor
Nicky Mehtani, MD, MPH
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francicso, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Results available

Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy

NCT01057693
View directory record Official record
Conditions
Diabetic Neuropathy, Painful
Interventions
pregabalin (Lyrica), Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
633 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
150
States / cities
Birmingham, Alabama • Northport, Alabama • Gilbert, Arizona + 120 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

NCT01559363
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Tesevatinib
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 62 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 7, 2026, 6:57 PM EDT
Recruiting Phase 2 Interventional

Prazosin for Alcohol Use Disorder With Withdrawal Symptoms

NCT04793685
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Prazosin, 12-Step Facilitation with Relapse Prevention and Contingency Management
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers

NCT02059291
View directory record Official record
Conditions
Hereditary Periodic Fevers
Interventions
Canakinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
1 Month and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Ann Arbor, Michigan • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

NCT01399918
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
everolimus and bevacizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2022 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 3 Interventional Results available

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

NCT03301220
View directory record Official record
Conditions
Smoldering Multiple Myeloma
Interventions
Daratumumab SC: daratumumab + rHuPH20
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
23
States / cities
Phoenix, Arizona • Whittier, California • Miami, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Results available

Relative Bioavailability of Pimasertib in Cancer Patients

NCT01992874
View directory record Official record
Conditions
Neoplasms
Interventions
Pimasertib Capsule (Part A), Pimasertib Tablet (Part A), Pimasertib Capsule (Part B and trial extension phase)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Sep 7, 2026, 6:57 PM EDT
Not listed Phase 1Phase 2 Interventional

Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs

NCT00319657
View directory record Official record
Conditions
Immune Tolerance
Interventions
Hematopoietic cell transplantation, Total lymphoid irradiation
Biological · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2021 · Synced Sep 7, 2026, 6:57 PM EDT
Withdrawn Phase 3 Interventional

A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)

NCT01157949
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Thymoglobulin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 7, 2026, 6:57 PM EDT
Withdrawn Phase 4 Interventional

Belatacept in Kidney Transplantation of Moderately Sensitized Patients

NCT02130817
View directory record Official record
Conditions
End Stage Renal Disease, Antibody Mediated Rejection
Interventions
Belatacept, Tacrolimus withdrawal, Plasmapheresis/Intravenous Immunoglobulin G, Thymoglobulin (ATG), Myfortic, Steroids
Drug · Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2018 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients

NCT01769768
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
LDE225, Wafarin, Bupropion
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
13
States / cities
Duarte, California • Kansas City, Kansas • Boston, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 7, 2026, 6:57 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Integrating Financial Coaching and Smoking Cessation Coaching

NCT05154669
View directory record Official record
Conditions
Smoking
Interventions
Financial counseling, Nicotine Replacement Therapy Agent - Patches, Nicotine Replacement Therapy Agent - Lozenges, Nicotine Replacement Therapy Agent - Gum
Other · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Enrollment
602 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 7, 2026, 6:57 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer

NCT05609370
View directory record Official record
Conditions
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
Interventions
Alcestobart, Tislelizumab, Bevacizumab or Bevacizumab biosimilar, Fluoropyrimidine (FP)
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
30
States / cities
Anchorage, Alaska • Gilbert, Arizona • Cerritos, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 4 Interventional Results available

Prevention of Recurrence in Depression With Drugs and CT

NCT00057577
View directory record Official record
Conditions
Depression
Interventions
Cognitive Therapy, Medications
Behavioral · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
3
States / cities
Chicago, Illinois • Philadelphia, Pennsylvania • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 7, 2026, 6:57 PM EDT
Active, not recruiting Phase 1 Interventional

BHV-7000 Responsive Neurostimulation System (RNS) Study

NCT07125261
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
BHV-700
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

Scoliosis-Specific Exercises for At-Risk AIS Curves

NCT02807545
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis
Interventions
Scoliosis Specific Exercises
Behavioral
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
10 Years to 17 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Louisville, Kentucky • Baltimore, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Not applicable Interventional

Use of SVS Device to Improve Outcomes for Neonatal Opioid Withdrawal Syndrome.

NCT04834297
View directory record Official record
Conditions
Neonatal Opioid Withdrawal Syndrome
Interventions
Prapela SVS mattress
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
0 Days to 2 Days
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation

NCT01685996
View directory record Official record
Conditions
Nicotine Dependence
Interventions
zonisamide, placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Phase 2 Interventional Results available

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

NCT02724020
View directory record Official record
Conditions
Clear-cell Metastatic Renal Cell Carcinoma
Interventions
Everolimus, MLN0128, MLN1117
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
Los Angeles, California • Venice, Florida • West Palm Beach, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 7, 2026, 6:57 PM EDT
Completed Not applicable Interventional Results available

Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus

NCT04301986
View directory record Official record
Conditions
Barrett Esophagus, GERD
Interventions
Cytosponge, Transnasal Endoscopy (TNE), Esophagogastroduodenoscopy
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2023 · Synced Sep 7, 2026, 6:57 PM EDT